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Abstract
Background: Microdeletion of the chromosome 22q11.2 region is the most common genetic
aberration among patients with velocardiofacial syndrome (VCFS) but a subset of subjects do not
show alterations of this chromosome region.
Methods: We analyzed 18 patients with VCFS-like features by comparative genomic hybridisation
(aCGH) array and performed a face-to-face slide hybridization with two different arrays: a whole
genome and a chromosome 22-specific BAC array. Putative rearrangements were confirmed by
FISH and MLPA assays.
Results:  One patient carried a combination of rearrangements on 1q21.1, consisting in a
microduplication of 212 kb and a close microdeletion of 1.15 Mb, previously reported in patients
with variable phenotypes, including mental retardation, congenital heart defects (CHD) and
schizophrenia. While 326 control samples were negative for both 1q21.1 rearrangements, one of
73 patients carried the same 212-kb microduplication, reciprocal to TAR microdeletion syndrome.
Also, we detected four copy number variants (CNVs) inherited from one parent (a 744-kb
duplication on 10q11.22; a 160 kb duplication and deletion on 22q11.21 in two cases; and a gain of
140 kb on 22q13.2), not present in control subjects, raising the potential role of these CNVs in the
VCFS-like phenotype.
Conclusions: Our results confirmed aCGH as a successful strategy in order to characterize
additional submicroscopic aberrations in patients with VCF-like features that fail to show
alterations in 22q11.2 region. We report a 212-kb microduplication on 1q21.1, detected in two
patients, which may contribute to CHD.
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Background
The hemizygous chromosome 22q11.2 microdeletion
occurs in approximately 1:4000-6000 live births [1,2],
being the most common genomic aberration among
patients clinically diagnosed with velocardiofacial syn-
drome (VCFS) or DiGeorge syndrome (DGS). Main clini-
cal symptoms include palatal abnormalities, particularly
velopharingeal incompetence, with feeding difficulties
reported in most (69%) young patients, conotruncal heart
defect, characteristic facial features (long face, broad/
tubular nose, hooded eyelids, hypertelorism, ear abnor-
malities and retrognathia), immune deficiency (involving
the respiratory tract in up to 77% of cases), motor and
developmental delay, learning disabilities, speech delay
and language deficits. Behavioural manifestations, such as
attention-deficit-hyperactivity disorder (ADHD) and
other psychiatric illness in adult patients are also frequent
[3-9]. Overall, more than 180 clinical features have been
associated with the 22q11.2 microdeletion syndrome
http://www.vcfsef.org[9].
The frequency of the 22q11.2 microdeletion varies with
the nature of the clinical findings. In infants with a con-
genital heart defect and no other apparent syndromic fea-
tures, or with a cleft palate alone, the frequency of
chromosome 22q11.2 microdeletion was reported to be
very low (0-1% and 1.8%) [10,11]. The wide phenotypic
spectrum and the highly diverse clinical features, which
frequently overlap with other defined or undefined clini-
cal entities, lead to difficulties in the clinical testing. Other
unrelated chromosomal abnormalities have been
reported in 2-4% of patients with suspect of VCFS, includ-
ing microscopic inversions and interchromosomal imbal-
ances, derivatives of parental translocations, marker
chromosomes, apparently balanced translocations, ring
chromosomes and sex chromosomes aneuploidies [12-
15]. Deletions involving contiguous genes on chromo-
some 10p have also been reported in some patients with
VCFS features [16-18], while mutations in gene T-box 1
(TBX1) account only for a few of reported cases [19,20].
Nowadays, in genetic testing laboratories, the most com-
mon procedure for the diagnosis of this syndrome is by
classical cytogenetic karyotyping, which is unable to
detect imbalances smaller than 5-10 megabases (Mb), and
by fluorescent in-situ hybridization (FISH) using commer-
cially available probes N25 or TUPLE1. FISH allows the
detection of the most common 3 Mb deletion as well as
the nested 1.5 Mb deletion. More recently, PCR-based
multiplex ligation-dependent probe amplification
(MLPA) has emerged as a cost-effective and accurate diag-
nostic tool for the analysis of imbalances in the 22q11.2
region. The commercial MLPA assay (Salsa P023B, MRC
Holland, The Netherlands) contains probes for several
other chromosomal regions such as 10p12-15, 8p21-p23,
4q22-q35, 17p13 and 18q21 based on findings of altera-
tions of these regions in a number of reported patients
with DGS/VCFS. However, there is still a subset of patients
with VCFS that does not show any chromosomal aberra-
tion detectable with the above-mentioned techniques.
Many of those VCFS-like patients present common clini-
cal features, like congenital heart disease (CHD), learning
disabilities and characteristic facial features, which suggest
that a common chromosomal imbalance could be the
underlying cause.
Array-based comparative genomic hybridization (aCGH)
has successfully been used for detecting genome dosage
alterations in children with mental retardation, dysmor-
phic features and in patients with CHD [21-24]. This tech-
nique dramatically increases the resolution and ability to
detect copy number alterations compared to conventional
cytogenetic methods and allows for a rapid genome-wide
screening of submicroscopic copy number aberrations.
Our study was designed to identify submicroscopic
genomic alterations important for the pathogenesis of
patients with VCFS-like features without the typical
22q11.2 microdeletion. We used two different array
designs as screening tools for whole genome and chromo-
some 22-specific analysis. We describe a novel region on
1q21.1 with a potentially important implication for the
CHD and VCFS-like clinical features, and identify several
copy number variants (CNVs) inherited from unaffected
parents which could contribute to the VCFS-like pheno-
type.
Methods
Patients
A total of 18 patients (9 male and 9 female, aged 5-23
years) with clinical features overlapping the VCF pheno-
type, referred to our laboratory to rule out 22q11.2 micro-
deletion, were analysed by custom-made BAC arrays. One
sample carrying a 22q11.2 deletion, previously detected
by FISH, and 20 normal population samples were also
included in the study to control the performance of the
arrays. All cases were recruited from the genetics service of
the Parc Taulí Health Corporation hospital and had clini-
cal assessments performed by medical doctors with wide
experience in treating patients with chromosomal abnor-
malities. Patients were included in the study on the basis
of the presence of VCFS clinical features. Previous labora-
tory studies on all patients included G-banding karyotype
at the level of 600 bands and FISH (Vysis LSI DiGeorge/
VCFS region Dual Color Probe) in metaphase and inter-
phase nuclei to rule out the presence of the 22q11.2
microdeletion and microduplication. The presence of
CGG-expansions of the FMR1 gene and/or subtelomeric
abnormalities (MLPA - Salsa P036C and P070, MRC-Hol-
land, Amsterdam, The Netherlands) were also excluded inBMC Medical Genetics 2009, 10:144 http://www.biomedcentral.com/1471-2350/10/144
Page 3 of 10
(page number not for citation purposes)
some patients with mental retardation. Written informed
consent was obtained after approval by the ethics board
committee of the Parc Taulí Health Corporation.
Genomic DNA was extracted from the whole blood of
patients using the Puregene DNA purification kit (QIA-
GEN-Gentra Systems) according to the manufacturer's
protocol. Pooled genomic DNA used as the reference in
aCGH experiments was extracted from blood of 50 male
or 50 female subjects.
CGH-BAC arrays
A face-to-face slide hybridization of the sample and refer-
ence DNAs on two different arrays was performed (see
below). The 5.6 K whole genome BAC array consists of
5,442 large insert DNA fragments (BACs) with a global
coverage of 23% of the euchromatic genome and a much
higher density in hotspot candidate regions, such as those
located between segmental duplications and all subte-
lomeres. The clone set used to produce this array was
mainly derived from the 32 K human BAC library from
the Children Hospital Oakland Research Institute http://
bacpac.chori.org/home.htm and several gaps in the
library were covered using BACs from other libraries
(mainly RP11). The distribution of BACs in the array is
not homogeneous, but the average spacing between con-
secutive clones is 0.5 Mb and the maximum 1.2 Mb. The
chromosome-22-specific tiling path array consists of 363
genomic BAC clones derived from the human chromo-
some 22. Slides contained triplicates of all clones provid-
ing an average density of at least one clone per 46 kb along
the entire euchromatic region of chromosome 22.
The production of the arrays was performed as described
by Cuscó et al. (2008) [25], probe preparation and
hybridizations were performed in the Microarray Unit of
the CRG, Barcelona, Spain. Briefly, for array preparation,
BAC DNA was isolated from 1.5 ml bacterial cultures
using the Montage BAC96 Miniprep kit following manu-
facturer's instructions (Millipore, Billerica, MA). DNA
amplification by DOP-PCR was done as described in Fie-
gler et al. (2003) [26]. PCR products were purified using
the Montage PCR96 Plates kit (Millipore, Billerica, MA)
and quantified using the PicoGreen dsDNA Quantifica-
tion kit (Invitrogen, Life technologies, Carlsbad, CA).
Purified products were dried, dissolved at 400 ng/μl in
50% DMSO and spotted using a VersArray ChipWriter™
Pro System (Bio-Rad).
Arrays were scanned using an Agilent G2565BA Microar-
ray Scanner System (Agilent Inc., Palo Alto, CA) and the
acquired images were analyzed using GenePix Pro 6.0
software (Axon, Molecular Devices) using the irregular
feature finding option. Extracted raw data was filtered and
Lowess normalized using Bacanal (Lozano et al., unpub-
lished), an in house web server implementation of the
Limma package developed within the Bioconductor
project in the R statistical programming environment. SD
of all 22-chromosome clones was calculated for each
hybridization experiment. Genomic imbalances were
determined based on the log2 of the Cy5/Cy3 ratios of the
average of the four replicates and regions were considered
as amplified or deleted when at least the absolute value of
two consecutive clones exceeded the 0.2 threshold.
Face-to-face slide hybridization
In order to save time, reagents and reduce experimental
noise, the same sample was simultaneously hybridized
onto the two different slides by arranging the two arrays
face to face in the same hybridization chamber (Corning®
Hybridization Chamber II with Increased Depth, Cultek).
Reversed-dye labelling of the samples was always per-
formed to minimize the effect of dye bias specific artifacts.
Each patient was hybridized against a sex-matched pool of
50 healthy controls. Hybridization was performed as
described by Wang et al. (2004) [27]. Briefly, 400 ng of
test and reference DNA were labelled by random priming
using the BioPrime Array CGH Genomic Labelling System
(Invitrogen, Life technologies, Carlsbad, CA). Cy3 and
Cy5 labelled test and control DNA precipitate together
with 100 μg of human Cot1 DNA and resuspended in 80
yl of hybridization buffer (50% formamida, 2 × SSC, 10%
dextran sulphate, 1× denhard's solution, 0.5 mM EDTA
pH 8, 40 mM NaPhosphatase pH 7). The two slides which
make up the pair were placed facing together slightly off-
set to create a lip along one edge. The barcodes on the
arrays created a small space between the slides. The
hybridization solution was slowly and carefully applied
along the lip and evenly occupied the space between the
slides.
Validation experiments
The copy number aberrations identified by aCGH, which
we considered for further validation, were analysed using
other molecular techniques such as MLPA and FISH anal-
ysis. When parental samples were available we checked by
MLPA the inheritance pattern of the alterations. The
MLPA probes were developed according to the procedures
described elsewhere http://www.mrc-holland.com and
using the MLPA Proseek algorithm [28]. The MLPA reac-
tions were performed as described by Schouten et al.,
2002 [29]. For the data analysis we calculated the relative
probe signals using the peak heights of PCR products.
Briefly, the tracing data was normalized by dividing each
probe's peak height by the total height of all peaks of the
sample and then dividing this value by the average nor-
malized peak's height of the corresponding locus of all the
samples. The product of this calculation is termed dosage
quotient (DQ). A DQ value below 0.65 was considered asB
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Table 1: Summary of altered regions, parental analysis and major clinical features in patients with velocardiofacial-like syndrome (VCFS-like) validated by multiplex ligation-dependent 
probe amplification (MLPA).
Sample 
GAIN
Sample 
LOSS
Altered 
clones
Region Size kb Start 
(Build 36)
End 
(Build 36)
Genes LOCUS 
(DGV)
MLPA 
probes
Inheritance Clinical features
V5 RP11-315I20
RP11-293J20
1q21.1 212 144149999 144361868 TXNIP, POLR3GL, 
ANKRD34, LIX1L, 
RBM8A, PEX11B, 
ITGA10, ANKRD35, 
PIAS3, NUDT17, 
POLR3C, ZNF364
Locus 0305 GNRH2 
PIAS3
de novo Cardiac anomalies (coarctation 
of the aorta); Velopharyngeal 
insufficiency; dysmorphic facial 
features; language impairment, 
mental retardation, cognitive 
and learning problems, 
immunological abnormalities.
V5 RP11-337C18
RP11-533N14
RP11-314N2
RP11-301M17
RP11-115G11
1q21.1 1,150 145073765 146329018 PRKAB2, FMO5, 
CHD1L, BCL9, 
ACP6, GJA5, GJA8, 
GPRB9
Locus 0305 BCL9 NBPF1 de novo
V26 RP11-314P12
RP11-292F22
RP11-192A16
RP11-30N1
RP11-115A11
10q11.22 743,52 46487806 47231326 PPYR1, ANXA8L, 
CTGLF4
Locus 2984 PPYR1 Paternal Mild dysmorphic facial features, 
mild mental retardation, 
psychological anomalies, phobias
V8 V24 RP11-818K20
RP11-444L7
22q11.21 159 19847992 20006849 - Locus 4746 RP11-444L7 Both Paternal V8: Dysmorphic facial features, 
learning disabilities mental 
retardation, father with 
schizophrenia
V24: Overt submucos palate, 
mild facial dysmorphic features, 
mild mental retardation, learning 
disabilities, autistic behaviour, 
(brother with cardiac anomalie)
V11 RP11-138G4 22q13.2 142 39422672 39564831 SLC25A17, ST13 SLC25A17b Maternal Dysmorphic facial features, 
learning disabilities, language 
impairment, attention deficit 
disorder
DGV, Database of Genomic Variants.BMC Medical Genetics 2009, 10:144 http://www.biomedcentral.com/1471-2350/10/144
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indicative of a deletion, and values above 1.3 are indica-
tive of duplications.
To confirm array results in patient V5, we performed fluo-
rescence in situ hybridization (FISH) experiments follow-
ing standard procedures. Furthermore to better
characterize the 1q21.1 microdeletion and microduplica-
tion of the 1q21.1 region in both cases (V5 and 112) we
used a custom array consisting of 130,000 isothermal
probes with 1,155 probes in the 1q21.1 region based on
Build 36 coordinates (chr1:143,500,000-148,000,000).
The experiments and the subsequent analyses of aCGH
were performed as previously described in detail [25,30].
Results
The whole-genome 5.6 K and the chromosome 22-spe-
cific BAC-arrays were used to study 18 patients with the
VCFS-like phenotype. We identified a total of 81 clones
with genomic dosage changes, belonging to 45 different
chromosomal regions (14 losses, 14 gains and 17 with sig-
nals in both directions) [see Additional file 1: Supplemen-
tal Table S1]. All chromosomal changes were compared
with the information deposited in the Database of
Genomic Variants (Build 36) http://projects.tcag.ca/varia
tion/[31]. 39 loci had been reported as CNVs in the data-
base and 20 of them were also detected as common vari-
ants in 20 control samples previously hybridized on the
same 5.6 K BAC-array [25]. The aim of this study was
screening for submicroscopic deletions and duplications
underlying several malformations such as heart defect,
palatal abnormalities or mental delay, for this reason
individual clones that were reported polymorphic in nor-
mal individuals and also the loci identified as variable in
our control samples were excluded. We selected eleven
loci for further MLPA validation, none of which were
present in control samples: six had not been previously
described as CNVs and five regions overlapped with previ-
ously reported CNVs, but had been chosen after the
imbalance of various consecutive clones in the samples
(encompassing regions >150 kb and up to 1.15 Mb) [see
Additional file 1: Supplemental Table S1]. Five of the
eleven CNVs identified by CGH were validated by MLPA
and screened by the same technique in parental samples
(Table 1). The remaining six loci could not be validated by
MLPA although at least two different probes per region
were assayed. Oligonucleotide sequences used for MLPA
are shown in Additional file 1: Supplemental Table S2.
Characterization of de novo genomic imbalances on 
chromosome 1q21.1
An interstitial microduplication spanning two overlap-
ping BAC clones, with an estimate size of 212 kb, and a
microdeletion spanning five consecutive clones, with an
estimate size of 1,15 Mb, on region 1q21.1 were found to
occur de-novo in patient V5. The duplicated region (aCGH
1q21.1(B36:chr1:144149999-144361868++)) included
12 RefSeq Genes (TXNIP, POLR3GL, ANKRD34A, LIX1L,
RBM8A, PEX11B, ITGA10, ANKRD35, PIAS3, NUDT17,
POLR3C, ZNF364), and the deleted region (aCGH 1q21.1
(B36:chr1:145073765-146329018)) encompassed eight
genes (PRKAB2, FMO5, CHD1L, BCL9, ACP6, GJA5,
GJA8, GPR89B, GPR89C, NBPF11) (Figure 1). FISH and
MLPA analysis confirmed both rearrangements in patient
V5, and excluded their presence in his parents (Figure 2).
This patient is a 17 year old male with cardiac anomalies
(coarctation of the aorta), some dysmorphic facial fea-
tures (frontal balding, arched eyebrows, eyes deeply set
and thin upper lip), velopharyngeal insufficiency with
reported feeding problems in infancy (gastroesophageal
reflux and frequent vomiting), language impairment,
moderate mental retardation, low cognitive deficit and
learning problems (irritability, attention deficit hyperac-
tivity disorder), immunological abnormalities (frequent
bronchitis), asthma, strabismus (surgery corrected at two
years), small umbilical hernia, and fingers with mild
camptodactyly, mild interdigital membrane and flat foot
arches (Figure 3-A). This patient was included in a previ-
ously published series that reported 22 probands with the
1q21.1 microdeletion [30]. We provide here additional
clinical information of this case.
We screen the 1q21.1 region, on 73 additional cases with
congenital heart defects by MLPA. We found one patient
(case 112) with the same microduplication but without
the contiguous deletion on 1q21.1, also present in his
unaffected father. The clinical features of this patient were
cardiac abnormalities (transposition of the great vessels,
ventricular septal defect, pulmonary stenosis and right
ventricular hypoplasia), braquicephaly and moderate
clinodactyly (Figure 3-B). We also analysed 326 addi-
tional control DNA samples obtained from anonymous
unrelated blood donors using the same MLPA probe mix.
All control samples were negative for both rearrange-
ments.
To carefully delineate alterations in the 1q21.1 region, the
samples V5 and 112 were also hybridized with a custom
oligo array with 1,155 probes being from the 1q21.1
region, as described in [30]. Results confirmed the com-
plex microduplication/microdeletion in case V5 and that
both patients shared the same microduplication, recipro-
cal to the TAR syndrome microdeletion [see Additional
file 2: Supplemental Figure S4].
Identification of inherited aberrations
Four of the validated aberrations were CNVs inherited
from one of the parents (Table 1), three overlapping with
loci previously reported as CNVs in the reference Database
of Genomic Variants http://projects.tcag.ca/variation/BMC Medical Genetics 2009, 10:144 http://www.biomedcentral.com/1471-2350/10/144
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[31]. A 744-kb duplication on 10q11.22 involving five
clones was identified in patient V26, showing facial dys-
morphism, learning disability, mild mental retardation
and behavioural problems. MLPA with one specific probe
on PPYR1 showed a gain in the patient and his father.
With the chromosome 22 tiling array we identified aber-
rations involving the deletion of two clones on the
22q11.2 region (160 kb) in two cases. Patients V8 and
V24 with dysmorphic facial features, low mental retarda-
tion and behavioural problems showed a gain and a loss
respectively, both paternally inherited. Finally, a gain of
BAC RP11-138G4, located on 22q13.2, which was mater-
nally inherited, was also identified with this chromo-
some-specific array. This region has not been reported in
the literature as a CNV and spans the SLC25A17 gene that
encodes a peroxisomal membrane protein belonging to
the family of mitochondrial solute carriers [OMIM
*606795]. This BAC clone also includes six exons of the
ST13  gene, encoding a highly conserved protein that
binds the major cytosolic chaperones heat-shock proteins
HSP70 and HSP90.
Discussion
The VCFS is a genomic disorder due to a hemizygous dele-
tion on chromosome 22q11.2. Our set of 18 patients
showed clinical features compatible with VCFS- like car-
diac anomalies, learning disabilities and characteristic
facial features but lacked the typical 22q11.2 deletion. We
screened our patients with VCF-like phenotypes with two
different custom-made aCGH (BAC-based whole genome
and chromosome 22 specific tiling path). The genome-
wide analysis of structural variations allowed us to iden-
tify de novo genomic rearrangements and inherited CNVs
in these patients.
Five out of the 11 altered regions selected for validation
were confirmed by MLPA, while the other six showed no
variation. Although the non-confirmed CNVs were
screened with two MLPA different probes, indicating that
Genomic imbalances on chromosome 1q21.1 Figure 1
Genomic imbalances on chromosome 1q21.1. A: 5.6K whole genome BAC aCGH profiles for patient V5 on chromo-
some region 1q21.1. Each dot represents the mean log2 ratio transformed after Lowess normalization (y-axis) from four inde-
pendent replicate spots on the array. The clones on the 1q21.1 region are displayed in the x-axis. Direct experiments (D) are 
shown in blue, while dye swap (DS) experiments are displayed in red. Each dot represents a BAC clone present in the aCGH 
experiment. B: Genome browser representation of the 1q21.1 region containing the microduplication/microdeletion. The fig-
ure shows the related segmental duplications that probably mediated the rearrangements and the genes affected. The microdu-
plication of 212 kb (reciprocal to the TAR syndrome micodeletion), and the downstream microdeletion of 1.15 Mb are 
indicated by two orange bars (GAIN and LOSS).
ABBMC Medical Genetics 2009, 10:144 http://www.biomedcentral.com/1471-2350/10/144
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they could be aCGH false positives, we have to consider
the possibility that the designed MLPA probes might lie
outside the BAC variable region. Recent reports indicate
that the size of the CNVs identified by BAC arrays is likely
to be overestimated. In fact, the concordance rate for
CNVs identified by two different platforms (BAC vs. SNP
arrays) was less than half (43%) when studying the same
individuals [32]. Concerning the five validated variations,
the analysis of parental samples revealed that four of them
were inherited. The presence of parents carrying these
CNVs but without clinically evident phenotypes raises the
issue of whether these CNVs are benign or pathogenic var-
iants with incomplete penetrance. Indeed, some well-
characterized syndromes such as the 22q11.2 microdele-
tion or the reciprocal microduplication, include pheno-
typically mild deletion carriers that have escaped clinical
recognition until they had children with more severe
manifestations. Furthermore, it is still possible that the
presence of an inherited CNV, especially deletions, could
be uncovering a recessive allele inherited from the other
parent. Further work in this direction would be required
to evaluate these hypotheses.
Two de-novo chromosome rearrangements were identified
by aCGH and MLPA analysis in one patient with VCFS-
like features. This is, to our knowledge, the first time that
this combination of two CNVs (an interstitial microdupli-
cation, spanning 2 BAC clones with an estimate size of
Detection and validation of the chromosome 1q21.1 rearrangements in patient V5 Figure 2
Detection and validation of the chromosome 1q21.1 rearrangements in patient V5. A: Electropherograms showing 
MLPA peak patterns corresponding to familial analysis of case V5. B: Interphase and metaphase FISH images with 1q21.1 red 
BAC probes confirm the microduplication (RP11-293J20) and microdeletion (RP11-314N2). A Green probe generated from 
CTD-2180H16 BAC clone was used as a control probe from same chromosome (1p34.2).
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Facial appearance and hands of patients with 1q21.1 rearangements Figure 3
Facial appearance and hands of patients with 1q21.1 rearangements. A: Patient V5 with microduplication/microdele-
tion 1q21.1: note frontal balding, arched eyebrows, deep-set eyes and thin upper lip, fingers with camptodactyly and mild inter-
digital membranes. B: Patient 112 with microduplication 1q21.1: Note moderate clinodactyly.
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212 kb (chr1: 144149999-144361868) and a contiguous
microdeletion spanning 5 BAC clones with an estimate
size of 1.15 Mb (chr1:145068638-146342725) is found
associated with such a phenotype.
This 1.15-Mb microdeletion was first reported in three
cases of CHD. The authors screened by real-time quantita-
tive PCR a total of 505 unrelated congenital heart disease
cases for deletions or duplications of Cx40 gene (GJA5)
and identified three cases with a 1.5 to 3-Mb deletion of
this region; however the microdeletion was also present in
some unaffected parents [33]. Recently, this 1.15 Mb
microdeletion has been associated with schizophrenia
and it has also been reported in individuals with consid-
erable phenotypic diversity including cardiac abnormali-
ties, mild-to-moderate mental retardation, microcephaly,
cataracts, mullerian aplasia, and autism [30,32-39]. Now-
adays, the main clinical features associated with this rear-
rangement are still unclear and the evaluation of family
members has revealed apparently unaffected carriers,
making genetic counselling difficult. However, the
absence of this rearrangement in more than 5,000 normal
individuals analyzed suggests that this structural variant is
rare, and probably contains important modifiers since it
exhibits incomplete penetrance.
Eight genes of this region could be involved in a wide vari-
ety of phenotypic features, at least two potentially
involved in cardiac defects: PRKAB2 and GJA5 (Cx40),
both expressed in the heart. A Cx40 heterozygous knock-
out mice (+/-) has been shown to develop a number of
cardiac malformations including bifid atrial appendage,
ventricular septal defect, tetralogy of Fallot and aortic arch
abnormalities [40]. GJA8  has previously been reported
associated with schizophrenia [41].
Although previous individuals have been found to carry
this microdeletion (1.15 Mb), this is the first time that it
is reported in concurrence with the contiguous microdu-
plication (212 kb). The only evident clinical feature
shared by the two cases reported here is the CHD. This
region contains numerous segmental duplications that
could mediate genomic rearrangements. Some larger rear-
rangements encompassing the 1q21.1 region have been
reported associated with varying phenotypes that
included dysmorphic features, hypotonia or mental retar-
dation. Among those, there are some cases with supernu-
merary marker or ring chromosomes derived from the
pericentromeric region of chromosome 1 plus q-arm
euchromatic fragments, [42-45]. Furthermore, it has been
reported that the reciprocal microdeletion of 1q21.1 is
necessary but not sufficient to cause TAR syndrome [46],
characterized by bilateral absence of the radii and throm-
bocytopenia, also the lower limbs, gastrointestinal, cardi-
ovascular and other systems may be involved [47].
Conclusions
In summary, this is the first study in which aCGH is used
to investigate patients with VCFS-like phenotype without
the classical 22q11.2 molecular rearrangement. aCGH
provides a successful strategy in order to characterize addi-
tional submicroscopic aberrations in patients that fail to
show alterations in 22q11.2. We have identified a rare and
de novo 1q21.1 microdeletion and a novel microduplica-
tion that could be associated with CHD. Further new cases
shall contribute to delineate more precisely the clinical
implications of these newly recognized genomic altera-
tions on 1q21.1 loci and their implication in CHD.
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